Webinars

Cancer remains one of the leading causes of death worldwide, with nearly one in six deaths attributed to it. Antibody-drug conjugates (ADCs) offer a promising therapeutic approach, but their success depends heavily on efficient antibody internalisation.

Join Dr. Ying Zhou on September 3rd 2025 at 7pm GMT, Product Manager at CUSABIO, as she unveils the potential of DT3C to transform ADC development and improve cancer treatment outcomes.

In this webinar, Dr. Kalina Paunovska will examine these challenges involving efficient delivery of RNA therapeutics in drug discovery and present SENT-seq (Single-cell Nanoparticle Targeting-sequencing), a high-throughput, single-cell multiomic screening platform designed to quantify LNP biodistribution, mRNA translation, and transcriptomic response in vivo.The webinar will discuss how SENT-seq addresses key limitations in nanoparticle screening and supports the rational design of novel LNPs tailored to specific cell types and therapeutic applications.

Register below to book your spot at the webinar on Wednesday 13th August at 16:00 BST